Eponyms

Diadem Awarded Patent in China for Its AlzoSure® Prognostic Biomarker Technology that Accurately Predicts Progression to Alzheimer's Disease

Retrieved on: 
Wednesday, August 4, 2021
Branches of biology, Cognitive disorders, Learning disabilities, Psychiatric diagnosis, Neuroscience, Psychiatry, Alzheimer's disease, Dementia, Eponyms

The patent, which covers key elements of the technology and testing protocol, provides protection through 2035.

Key Points: 
  • The patent, which covers key elements of the technology and testing protocol, provides protection through 2035.
  • "According to the Chinese Geriatrics Society, the number of Alzheimer's patients in China is expected toexceed 40 million by 2050.
  • Early identification has never been more important as interventions to slow or halt disease progression are now becoming available.
  • Diadem is preparing for rapid commercialization of its initial Alzheimer's prognostic via a global launch in collaboration with strategic partners.

BioVie Presents Data Supporting use of NE3107 in the Treatment of Alzheimer’s Disease at 2021 Alzheimer’s Association International Conference

Retrieved on: 
Tuesday, July 27, 2021
Branches of biology, Diabetes, Neuroscience, Alzheimer's disease, Amyloidosis, Dementia, Eponyms, Insulin resistance, Psychiatry

BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).

Key Points: 
  • BioVie has obtained authorization from the U.S. Food & Drug Administration to initiate a pivotal Phase 3 trial of NE3107 in Alzheimers Disease called the NM101 study ( NCT04669028 ).
  • NM101 is a randomized double blind, placebo-controlled, US multicenter study of NE3107 in 316 subjects with mild to moderate Alzheimers Disease.
  • At the AAIC this year there are literally hundreds of presentations on inflammation and Alzheimers disease and dozens on insulin resistance and AD.
  • NE3107 is the first potentially disease modifying, anti-inflammatory insulin sensitizer therapy in a phase 3 trial, said Cuong Do, Chief Executive Officer of BioVie.